A Single-arm Phase II Study of HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients with KRAS G12D Mutations
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs HRS 4642 (Primary) ; Nimotuzumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 20 Jan 2025 New trial record